Julie Min Jeung Paik, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dipeptidyl-Peptidase IV Inhibitors | 9 | 2024 | 292 | 2.550 |
Why?
|
Spinal Fractures | 6 | 2022 | 698 | 2.540 |
Why?
|
Renal Insufficiency, Chronic | 13 | 2023 | 2195 | 2.360 |
Why?
|
Hyperkalemia | 2 | 2023 | 218 | 1.520 |
Why?
|
Polypharmacy | 3 | 2021 | 294 | 1.370 |
Why?
|
Diabetic Nephropathies | 3 | 2022 | 983 | 1.370 |
Why?
|
Diabetes Mellitus, Type 2 | 16 | 2024 | 11695 | 1.270 |
Why?
|
Hip Fractures | 3 | 2022 | 954 | 1.200 |
Why?
|
Geriatrics | 2 | 2022 | 396 | 1.130 |
Why?
|
Nephrology | 2 | 2019 | 260 | 1.060 |
Why?
|
Pharmacists | 3 | 2019 | 240 | 0.870 |
Why?
|
Nephrolithiasis | 1 | 2024 | 110 | 0.860 |
Why?
|
Fractures, Bone | 5 | 2023 | 1945 | 0.840 |
Why?
|
Hypoglycemic Agents | 13 | 2024 | 2866 | 0.840 |
Why?
|
Diabetic Ketoacidosis | 2 | 2023 | 247 | 0.830 |
Why?
|
Kidney Failure, Chronic | 4 | 2021 | 2536 | 0.770 |
Why?
|
Veterans | 7 | 2023 | 2513 | 0.740 |
Why?
|
Calcium | 5 | 2023 | 5753 | 0.710 |
Why?
|
Renal Dialysis | 6 | 2021 | 1780 | 0.700 |
Why?
|
International Classification of Diseases | 2 | 2021 | 865 | 0.690 |
Why?
|
House Calls | 1 | 2020 | 159 | 0.670 |
Why?
|
Kidney | 6 | 2023 | 7167 | 0.660 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2022 | 269 | 0.640 |
Why?
|
Cardiovascular Diseases | 10 | 2024 | 15108 | 0.600 |
Why?
|
Histamine H2 Antagonists | 1 | 2018 | 165 | 0.580 |
Why?
|
Proton Pump Inhibitors | 2 | 2018 | 521 | 0.560 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2016 | 76 | 0.560 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 202 | 0.550 |
Why?
|
Parathyroid Hormone | 3 | 2012 | 1801 | 0.550 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3667 | 0.530 |
Why?
|
Waist Circumference | 1 | 2019 | 917 | 0.520 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 135 | 0.520 |
Why?
|
Glomerulosclerosis, Focal Segmental | 2 | 2015 | 359 | 0.500 |
Why?
|
Wrist Injuries | 1 | 2017 | 208 | 0.490 |
Why?
|
Nephrotic Syndrome | 2 | 2015 | 389 | 0.480 |
Why?
|
Hyponatremia | 1 | 2016 | 298 | 0.460 |
Why?
|
Patient Care | 1 | 2019 | 639 | 0.450 |
Why?
|
Gout | 2 | 2017 | 556 | 0.450 |
Why?
|
Benzhydryl Compounds | 4 | 2024 | 840 | 0.450 |
Why?
|
Body Mass Index | 4 | 2019 | 12695 | 0.440 |
Why?
|
Heart Failure | 5 | 2024 | 10856 | 0.440 |
Why?
|
Osteoporotic Fractures | 1 | 2017 | 403 | 0.430 |
Why?
|
Cohort Studies | 21 | 2024 | 40450 | 0.410 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1636 | 0.410 |
Why?
|
Calcium, Dietary | 2 | 2023 | 527 | 0.400 |
Why?
|
Glucosides | 4 | 2024 | 446 | 0.400 |
Why?
|
Osteoporosis | 2 | 2021 | 1581 | 0.380 |
Why?
|
Aged | 33 | 2024 | 162944 | 0.380 |
Why?
|
Dietary Supplements | 2 | 2014 | 3294 | 0.370 |
Why?
|
Hyperthyroidism | 1 | 2012 | 293 | 0.370 |
Why?
|
Medication Adherence | 2 | 2022 | 2055 | 0.360 |
Why?
|
Nurses | 3 | 2023 | 2459 | 0.350 |
Why?
|
Phosphorus | 1 | 2010 | 338 | 0.340 |
Why?
|
Stroke | 5 | 2024 | 9963 | 0.330 |
Why?
|
Humans | 64 | 2024 | 742088 | 0.320 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2020 | 1808 | 0.300 |
Why?
|
Bone Density | 2 | 2017 | 3469 | 0.290 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11690 | 0.280 |
Why?
|
Glucocorticoids | 2 | 2015 | 2107 | 0.280 |
Why?
|
Frail Elderly | 2 | 2022 | 691 | 0.270 |
Why?
|
United States | 25 | 2024 | 69693 | 0.260 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 774 | 0.260 |
Why?
|
Glomerular Filtration Rate | 3 | 2023 | 2167 | 0.260 |
Why?
|
Medicare | 11 | 2024 | 6532 | 0.250 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1656 | 0.250 |
Why?
|
Geriatric Assessment | 3 | 2022 | 1369 | 0.250 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4248 | 0.250 |
Why?
|
Female | 38 | 2024 | 379592 | 0.250 |
Why?
|
Prospective Studies | 11 | 2023 | 53187 | 0.240 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2016 | 155 | 0.230 |
Why?
|
Telemedicine | 1 | 2020 | 2853 | 0.220 |
Why?
|
Algorithms | 2 | 2021 | 13853 | 0.220 |
Why?
|
Adult | 25 | 2024 | 213712 | 0.220 |
Why?
|
Atherosclerosis | 3 | 2024 | 3428 | 0.220 |
Why?
|
Silicates | 1 | 2022 | 42 | 0.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3239 | 0.210 |
Why?
|
Middle Aged | 26 | 2024 | 213127 | 0.200 |
Why?
|
Pruritus | 2 | 2015 | 359 | 0.200 |
Why?
|
Minerals | 1 | 2023 | 275 | 0.200 |
Why?
|
Sodium | 2 | 2024 | 1627 | 0.200 |
Why?
|
Glucose | 5 | 2024 | 4391 | 0.200 |
Why?
|
Hydromorphone | 1 | 2021 | 65 | 0.190 |
Why?
|
Risk Assessment | 6 | 2021 | 23320 | 0.190 |
Why?
|
Snoring | 1 | 2022 | 189 | 0.190 |
Why?
|
Self Report | 3 | 2022 | 3548 | 0.180 |
Why?
|
Risk Factors | 14 | 2023 | 72145 | 0.180 |
Why?
|
Atrial Fibrillation | 3 | 2023 | 5019 | 0.180 |
Why?
|
Vitamin D | 4 | 2023 | 3211 | 0.180 |
Why?
|
Phosphates | 1 | 2023 | 786 | 0.170 |
Why?
|
Education, Pharmacy | 1 | 2019 | 35 | 0.170 |
Why?
|
Hypertension | 2 | 2016 | 8455 | 0.170 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 40 | 0.170 |
Why?
|
Lithium | 1 | 2022 | 601 | 0.160 |
Why?
|
Calcium Phosphates | 1 | 2019 | 171 | 0.160 |
Why?
|
Cold Ischemia | 1 | 2018 | 65 | 0.160 |
Why?
|
Incidence | 8 | 2018 | 20928 | 0.160 |
Why?
|
Fentanyl | 1 | 2021 | 410 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 664 | 0.150 |
Why?
|
Chelating Agents | 1 | 2019 | 380 | 0.150 |
Why?
|
Vitamin A | 2 | 2011 | 615 | 0.150 |
Why?
|
Prospective Payment System | 1 | 2018 | 133 | 0.150 |
Why?
|
Hearing | 1 | 2021 | 479 | 0.150 |
Why?
|
Male | 22 | 2024 | 349538 | 0.150 |
Why?
|
Publication Bias | 1 | 2017 | 161 | 0.150 |
Why?
|
Pilot Projects | 2 | 2020 | 8297 | 0.140 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 132 | 0.140 |
Why?
|
Hypoglycemia | 1 | 2023 | 859 | 0.140 |
Why?
|
Diphosphonates | 1 | 2021 | 625 | 0.140 |
Why?
|
Metformin | 1 | 2023 | 829 | 0.140 |
Why?
|
Hospice Care | 1 | 2023 | 671 | 0.140 |
Why?
|
Pyrazoles | 2 | 2023 | 1970 | 0.140 |
Why?
|
Hyperparathyroidism | 1 | 2017 | 339 | 0.130 |
Why?
|
Tissue and Organ Harvesting | 1 | 2018 | 355 | 0.130 |
Why?
|
Administration, Oral | 2 | 2021 | 3913 | 0.130 |
Why?
|
Proteinuria | 2 | 2015 | 657 | 0.130 |
Why?
|
Polymers | 1 | 2022 | 1618 | 0.120 |
Why?
|
Needs Assessment | 1 | 2020 | 1146 | 0.120 |
Why?
|
Body Size | 1 | 2017 | 461 | 0.120 |
Why?
|
Comorbidity | 2 | 2020 | 10372 | 0.120 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12958 | 0.120 |
Why?
|
Drug Interactions | 1 | 2018 | 1458 | 0.120 |
Why?
|
Hearing Loss | 1 | 2021 | 765 | 0.120 |
Why?
|
Dermatomyositis | 1 | 2016 | 223 | 0.120 |
Why?
|
Suicide, Attempted | 1 | 2022 | 1218 | 0.110 |
Why?
|
Interviews as Topic | 1 | 2020 | 2536 | 0.110 |
Why?
|
Spine | 1 | 2020 | 1143 | 0.110 |
Why?
|
Interprofessional Relations | 1 | 2019 | 1008 | 0.110 |
Why?
|
Hospitalization | 3 | 2023 | 10232 | 0.110 |
Why?
|
Inpatients | 1 | 2024 | 2495 | 0.110 |
Why?
|
Bone and Bones | 1 | 2023 | 2575 | 0.100 |
Why?
|
Ultraviolet Rays | 1 | 2017 | 1059 | 0.100 |
Why?
|
Sulfonylurea Compounds | 2 | 2023 | 204 | 0.100 |
Why?
|
Retrospective Studies | 9 | 2024 | 77098 | 0.100 |
Why?
|
Kidney Calculi | 1 | 2015 | 465 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1597 | 0.100 |
Why?
|
Sex Factors | 2 | 2017 | 10392 | 0.100 |
Why?
|
Age Factors | 3 | 2019 | 18355 | 0.100 |
Why?
|
Mexican Americans | 1 | 2011 | 166 | 0.090 |
Why?
|
Longitudinal Studies | 3 | 2022 | 13921 | 0.090 |
Why?
|
Uric Acid | 2 | 2016 | 760 | 0.090 |
Why?
|
Antihypertensive Agents | 2 | 2021 | 2043 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 9941 | 0.090 |
Why?
|
Pain Measurement | 1 | 2019 | 3418 | 0.090 |
Why?
|
Aspirin | 1 | 2021 | 3278 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1967 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2145 | 0.080 |
Why?
|
Pyridones | 2 | 2023 | 712 | 0.080 |
Why?
|
Lung Diseases, Interstitial | 1 | 2016 | 807 | 0.080 |
Why?
|
Adolescent | 4 | 2024 | 85649 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8662 | 0.080 |
Why?
|
Demography | 1 | 2011 | 1650 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2948 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2900 | 0.070 |
Why?
|
Databases, Factual | 1 | 2021 | 7716 | 0.070 |
Why?
|
Health Surveys | 1 | 2016 | 4030 | 0.070 |
Why?
|
Sleep | 1 | 2022 | 4604 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15056 | 0.070 |
Why?
|
Aged, 80 and over | 2 | 2021 | 57683 | 0.070 |
Why?
|
Graft Rejection | 1 | 2018 | 4393 | 0.060 |
Why?
|
Diet | 2 | 2014 | 7923 | 0.060 |
Why?
|
Bipolar Disorder | 1 | 2022 | 5024 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5724 | 0.060 |
Why?
|
Seasons | 1 | 2010 | 1492 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 2130 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2022 | 4628 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3738 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9679 | 0.060 |
Why?
|
Creatinine | 2 | 2023 | 1916 | 0.060 |
Why?
|
Prevalence | 1 | 2020 | 15194 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5133 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2018 | 4246 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12242 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40054 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 88 | 0.050 |
Why?
|
Iohexol | 1 | 2023 | 196 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14720 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2016 | 24913 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 250 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12344 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5978 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2021 | 85 | 0.050 |
Why?
|
Nurse's Role | 1 | 2023 | 209 | 0.050 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 98 | 0.050 |
Why?
|
Milk | 1 | 2023 | 449 | 0.050 |
Why?
|
Audiometry | 1 | 2021 | 242 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8328 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5425 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 56350 | 0.040 |
Why?
|
Dairy Products | 1 | 2023 | 498 | 0.040 |
Why?
|
Life Style | 1 | 2011 | 3824 | 0.040 |
Why?
|
Exercise | 1 | 2016 | 5611 | 0.040 |
Why?
|
Health Status | 1 | 2012 | 4030 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 6078 | 0.040 |
Why?
|
Antimanic Agents | 1 | 2022 | 522 | 0.040 |
Why?
|
Anticoagulants | 2 | 2023 | 4595 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 874 | 0.040 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2016 | 87 | 0.030 |
Why?
|
Total Lung Capacity | 1 | 2016 | 143 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1130 | 0.030 |
Why?
|
Maine | 1 | 2016 | 139 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39004 | 0.030 |
Why?
|
Warfarin | 1 | 2023 | 1493 | 0.030 |
Why?
|
Furosemide | 1 | 2015 | 167 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2271 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2022 | 1246 | 0.030 |
Why?
|
Propensity Score | 1 | 2019 | 1771 | 0.030 |
Why?
|
Calcinosis | 1 | 2019 | 1497 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4392 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4929 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2015 | 802 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6575 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2022 | 3058 | 0.020 |
Why?
|
Graft Survival | 1 | 2018 | 3733 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12017 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 5979 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10248 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2021 | 62966 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8077 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12773 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6454 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168561 | 0.010 |
Why?
|